For most patients with end-stage heart failure, heart transplantation is the treatment of
choice. Allograft rejection is one of the major post-transplantation complications affecting …

Abstract Purpose of Review Recent developments in high-throughput DNA and RNA
sequencing technologies have facilitated the development of noninvasive assays to monitor …

Recent technical advances in the field of quantitative proteomics have stimulated a large
number of biomarker discovery studies of various diseases, providing avenues for new …

Although decades of the reductionist approach achieved great milestones in optimizing the
immunosuppression therapy, traditional clinical parameters still fail in predicting both acute …

The number of heart transplants performed annually in the United States and worldwide
continues to increase, but there has been little change in graft longevity and patient survival …

Background Peripheral blood-based gene expression patterns have been investigated as
biomarkers to monitor the immune system and rule out rejection after heart transplantation …

The field of biomarker discovery made a significant leap over the past few decades. As we
enter the Era of the Human Genome, thousands of biomarkers can be identified in a …

Heart transplantation (HTx) is considered the gold-standard therapy for the treatment of
advanced heart failure (HF). The long-term survival in HTx is hindered by graft failure which …

Endomyocardial biopsy remains the most reliable method of detecting rejection following
cardiac transplantation. Despite numerous attempts to detect rejection using a blood assay …

Novel biomarkers of allograft rejection: ‘omics’ approaches... : Current Opinion in Organ
Transplantation Novel biomarkers of allograft rejection: ‘omics’ approaches start to deliver …